
# Title 21 - Food and Drugs
## Chapter I - Food and Drug Administration, Department of Health and Human Services
### Subchapter C - Drugs: General
#### PART 201 - LABELING
##### Subpart G - Specific Labeling Requirements for Specific Drug Products
###### ยง 201.326 Over-the-counter drug products containing internal analgesic/antipyretic active ingredients; required warnings and other labeling.
####### New warnings information statement.

(b)The labeling of any drug product subject to this section that is initially introduced or initially delivered for introduction into interstate commerce before or on April 29, 2010, must bear on its PDP, as defined in ยง 201.60, the statement "See new warnings information". This statement must appear highlighted (e.g., fluorescent or color contrast) or in bold type, be in lines generally parallel to the base on which the package rests as it is designed to be displayed, and be in one of the following sizes, whichever is greater:

(1) At least one-quarter as large as the size of the most prominent printed matter on the PDP, or

(2) At least as large as the size of the "Drug Facts" title, as required in ยง 201.66(d)(2). The new warnings information statement must remain on the PDP of the drug product for at least 1 year from the date the product is initially introduced into interstate commerce.
